全文获取类型
收费全文 | 736篇 |
免费 | 33篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 56篇 |
妇产科学 | 32篇 |
基础医学 | 75篇 |
口腔科学 | 10篇 |
临床医学 | 31篇 |
内科学 | 114篇 |
皮肤病学 | 10篇 |
神经病学 | 43篇 |
特种医学 | 9篇 |
外科学 | 145篇 |
综合类 | 1篇 |
预防医学 | 89篇 |
眼科学 | 18篇 |
药学 | 27篇 |
中国医学 | 1篇 |
肿瘤学 | 112篇 |
出版年
2022年 | 11篇 |
2021年 | 14篇 |
2020年 | 7篇 |
2019年 | 9篇 |
2018年 | 11篇 |
2017年 | 10篇 |
2016年 | 14篇 |
2015年 | 13篇 |
2014年 | 14篇 |
2013年 | 34篇 |
2012年 | 56篇 |
2011年 | 34篇 |
2010年 | 26篇 |
2009年 | 22篇 |
2008年 | 31篇 |
2007年 | 45篇 |
2006年 | 45篇 |
2005年 | 43篇 |
2004年 | 36篇 |
2003年 | 43篇 |
2002年 | 30篇 |
2001年 | 18篇 |
2000年 | 22篇 |
1999年 | 19篇 |
1998年 | 11篇 |
1997年 | 6篇 |
1996年 | 7篇 |
1995年 | 7篇 |
1994年 | 5篇 |
1993年 | 5篇 |
1992年 | 5篇 |
1991年 | 7篇 |
1990年 | 7篇 |
1989年 | 7篇 |
1988年 | 5篇 |
1987年 | 13篇 |
1986年 | 9篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1981年 | 4篇 |
1979年 | 6篇 |
1978年 | 7篇 |
1977年 | 3篇 |
1976年 | 7篇 |
1975年 | 4篇 |
1974年 | 8篇 |
1973年 | 4篇 |
1972年 | 3篇 |
1970年 | 3篇 |
1968年 | 3篇 |
排序方式: 共有773条查询结果,搜索用时 15 毫秒
1.
Paolo Cossu Rocca Matteo Brunelli Stefano Gobbo Albino Eccher Emma Bragantini Maria M Mina Vincenzo Ficarra Filiberto Zattoni Alberto Zamò Maurizio Pea Aldo Scarpa Marco Chilosi Fabio Menestrina Franco Bonetti John N Eble Guido Martignoni 《Modern pathology》2007,20(7):722-728
S100A1 is a calcium-binding protein, which has been recently found in renal cell neoplasms. We evaluated the diagnostic utility of immunohistochemical detection of S100A1 in 164 renal cell neoplasms. Forty-one clear cell, 32 papillary, and 51 chromophobe renal cell carcinomas, and 40 oncocytomas, 164 samples of normal renal parenchyma adjacent to the tumors and 13 fetal kidneys were analyzed. The levels of S100A1 mRNA detected by quantitative RT-PCR analysis of frozen tissues from seven clear cell, five papillary, and six chromophobe renal cell carcinomas, four oncocytomas, and nine samples of normal renal tissues adjacent to neoplasms were compared with the immunohistochemical detection of protein expression. Clear cell and papillary renal cell carcinomas showed positive reactions for S100A1 in 30 out of 41 tumors (73%) and in 30 out of 32 (94%) tumors, respectively. Thirty-seven renal oncocytomas out of 40 (93%) were positive for S100A1, whereas 48 of 51 (94%) chromophobe renal cell carcinomas were negative. S100A1 protein was detected in all samples of unaffected and fetal kidneys. S100A1 mRNA was detected by RT-PCR in all normal kidneys and renal cell neoplasms, although at very different levels. Statistical analyses comparing the different expression of S100A1 in clear cell and chromophobe renal cell carcinomas observed by immunohistochemical and RT-PCR methods showed significant values (P<0.001), such as when comparing by both techniques the different levels of S100A1 expression in chromophobe renal cell carcinomas and oncocytomas (P<0.001). Our study shows that S100A1 protein is expressed in oncocytomas, clear cell and papillary renal cell carcinomas but not in chromophobe renal cell carcinomas. Its immunodetection is potentially useful for the differential diagnosis between chromophobe renal cell carcinoma and oncocytoma. Further, S100A1 protein expression is constantly detected in the normal parenchyma of the adult and fetal kidney. 相似文献
2.
L Troncone R Riccardi P Montemaggi V Rufini A Lasorella R Mastrangelo 《Medical and pediatric oncology》1987,15(4):220-223
Seven patients with neuroblastoma (six children and one adult) were treated with therapeutic doses of high specific activity 131I-metaiodobenzylguanidine (131I-MIBG). Six patients were in stage IV and unresponsive to conventional treatment. One patient, in stage III, was treated at diagnosis, an approach never previously reported. Single doses of 131I-MIBG varying from 70 to 184 mCi split into two parts were administered by slow i.v. infusion (4 to 8 hours) at 2- to 4-day intervals. The following results were obtained in the six evaluable patients: two patients showed transient stabilization of the disease; three had an objective response, with shrinking of the primary tumor and/or regression of the metastatic lesions. Of these three patients, two suffered relapses at 2 and 7 months, respectively, from the first course of MIBG. The third patient, in whom the residual disease almost completely disappeared following MIBG therapy, is still alive in complete remission after autologous bone marrow transplantation with a follow-up of 14 months. The single patient treated at diagnosis showed a dramatic response to a relatively low dosage of MIBG, with histologically proved disappearance of the tumor mass. Our data indicate that MIBG may be useful in the treatment of neuroblastoma unresponsive to conventional chemotherapy. The complete response observed in the patient treated at diagnosis suggests that the full potentiality of MIBG therapy should be explored in untreated patients. 相似文献
3.
John C Criscione Filiberto Rodriguez D Craig Miller 《European journal of cardio-thoracic surgery》2005,28(2):363-4; author reply 364-7
4.
5.
Influence of smoking habit on the frequency of micronuclei in human lymphocytes by the cytokinesis block method 总被引:2,自引:1,他引:2
To evaluate the frequency of micronucleated lymphocytes in a normal population, 45 healthy subjects were analysed by using a modified cytochalasin B block method; the influence of some confounding factors (sex, age, smoking, etc.) were taken into account. Using a stepwise regression test smoking habits were found to have a statistically significant influence on the frequency of micronucleated cells and micronuclei. In addition, the mitotic and proliferative indexes, and the frequency of micronucleated lymphocytes, at different culture times, were studied in four healthy subjects. Based on the results we suggest that cytochalasin B be added to cultures no later than the 42nd hour. 相似文献
6.
D Berd M J Mastrangelo 《Methods and findings in experimental and clinical pharmacology》1987,9(9):569-577
The oxazaphosphorine drug cyclophosphamide (CY), has significant immunopotentiating effects. Maguire and Ettore (21) were the first workers to describe CY-mediated immunopotentiation: They reported that guinea pigs treated with CY and then contact-sensitized developed much more intense and prolonged allergic contact dermatitis reactions than did control guinea pigs that had received sensitizer alone. Subsequently, CY was shown to immunopotentiate the acquisition of delayed-type hypersensitivity (DTH) to a variety of antigens and even to syngeneic tissue. The critical factor determining whether CY depresses or potentiates an immune response in experimental animals is the timing of administration of CY and antigen. The dose of CY seems to be much less important. Since 1982, we have performed immunological studies of 74 cancer patients treated with CY. We have tested two doses--1000 mg/M2 and 300 mg/M2, given by rapid intravenous infusion. Using the animal data as a guide, we have elected to administer CY 3 days prior to sensitization with antigen. Our initial two studies were performed with the primary antigen keyhole limpet hemocyanin (KLH): patients with advanced cancer were either sensitized with KLH alone or with KLH 3 days after administration of CY, 1000 mg/M2 ("high dose") or 300 mg/M2 ("low dose"). We found that pretreatment of patients with CY, at either "high" or "low" dose, significantly augmented the development of DTH to KLH. In contrast, the antibody response to KLH was potentiated by pretreatment with "low" dose CY, but not with "high" dose CY. DTH responses to microbial recall antigens (trichophyton, mumps, candida) were not augmented by CY administration.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
7.
8.
Dr. Maurizio Vaglini MD Dr. Filiberto Belli MD Mario Santinami MD Flavio Arienti MD Giorgio Parmiani MD Laura Persiani MD Nicola Santoro MD Maria Grazia Inglese MD Fortunato D'Elia MD Natale Cascinelli MD 《Annals of surgical oncology》1995,2(1):61-70
Background: Therapies of advanced melanoma patients with interleukin-2 (IL-2) and cytotoxic lymphocytes have produced interesting results, but a larger diffusion of these treatments is limited by the severe side effects due to IL-2 systemic infusion. A strictly regional administration of IL-2 and cells by an isolation perfusion (IP) in extracorporeal circulation (ECC) for the treatment of regional melanoma metastases could improve tolerability and efficacy of this specific modality of immunotherapy.
Methods: Ten patients were submitted to adoptive immunotherapy with IL-2 and lymphokine-activated killer (LAK) cells by IP in ECC. The schedule of treatment included the first course of a 5-day systemic administration of IL-2 (Proleukin, EuroCetus 9–12 × 106 IU/M2/day continuous infusion); autologous LAK cells were obtained via leukapheresis and after in vitro activation were given (range 8–28 × 109) along with IL-2 (120-2,400 IU/ml of perfusion priming) to the affected limb by IP; IL-2 (9–12×106 IU/m2/day) was also administered by systemic continuous infusion for 5 days starting on the day after IP.
Results: All patients concluded the treatment without any major local or systemic toxicities. Clinical responses included one complete and six partial remissions; three patients had stable disease. All patients are alive. Follow-up after IP ranged from 12 to 35 months (median: 22). The analysis of circulating lymphocytes revealed the rapid disappearance of LAK cells, suggesting their extravasation and/or endothelial adhesion in perfused tissues.
Conclusions: IP with IL-2 and LAK cells is a new approach for the treatment of in-transit metastases due to cutaneous melanoma. The treatment appears to be feasible and reliable. Further biological and immunological studies should permit amelioration of the present modality of treatment. 相似文献
9.
10.
Roberto Lorusso Samuel Heuts Federica Jiritano Roberto Scrofani Carlo Antona Guglielmo Actis Dato Paolo Centofanti Sandro Ferrarese Matteo Matteucci Antonio Miceli Mattia Glauber Enrico Vizzardi Sandro Sponga Igor Vendramin Andrea Garatti Carlo de Vincentis Michele De Bonis Silvia Ajello Giovanni Troise Margherita Dalla Tomba Filiberto Serraino 《Interactive Cardiovascular and Thoracic Surgery》2022,35(1)
Open in a separate window OBJECTIVESAlthough the intra-aortic balloon pump (IABP) has been the most widely adopted temporary mechanical support device in cardiac surgical patients, its use has declined. The current study aimed to evaluate the occurrence and predictors of early mortality and complication rates in contemporary cardiac surgery patients supported by an IABP.METHODSA multicentre, retrospective analysis was performed of all consecutive cardiac surgical patients receiving perioperative balloon pump support in 8 centres between January 2010 to December 2019. The primary outcome was early mortality, and secondary outcomes were balloon-associated complications. A multivariable binary logistic regression model was applied to evaluate predictors of the primary outcome.RESULTSThe study cohort consisted of 2615 consecutive patients. The median age was 68 years [25th percentile 61, 75th percentile 75 years], with the majority being male (76.9%), and a mean calculated 30-day mortality risk of 10.0%. Early mortality was 12.7% (n = 333), due to cardiac causes (n = 266), neurological causes (=22), balloon-related causes (n = 5) and other causes (n = 40). A composite end point of all vascular complications occurred in 7.2% of patients, and leg ischaemia was observed in 1.3% of patients. The most important predictors of early mortality were peripheral vascular disease [odds ratio (OR) 1.63], postoperative dialysis requirement (OR 10.40) and vascular complications (OR 2.57).CONCLUSIONSThe use of the perioperative IABP proved to be safe and demonstrated relatively low complication rates, particularly for leg ischaemia. As such, we believe that specialists should not be held back to use this widely available treatment in high-risk cardiac surgical patients when indicated. 相似文献